A dermatologist's perspective of the
            <scp>COVID</scp>
            ‐19 outbreak

Murrell, Dédée F.; Arora, Gulhima; Rudnicka, Lidia; Kassir, Martin; Lotti, Torello; Goldust, Mohamad

doi:10.1111/dth.13538

Cited by 13 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 On March 11, 2020 World Health Organization (WHO) declared COVID 19 as pandemic. 3,4 There have been many proposed theories on the effect of this SARS-Cov-2 virus on the human immune system. In general, low immunity allows rapid viral replication and delays viral clearance from the body.…”

Section: Introductionmentioning

confidence: 99%

COVID‐19 and immunosuppressive therapy in dermatology

Schwartz

Pradhan

Murrell

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Coronavirus 2019 (COVID 19) was first detected in December 2019 in China. It has become a pandemic. With concern about therapies that may decrease immunity and enhance the severity of an indivduals's COVID‐19 infection, leading to a possibly fatal outcome, use of immunosuppressants has become an important concern. This work focuses on management of various skin diseases individuals lacking immunity to COVID‐19 but requiring a systemic immunosuppressant, keeping in view the challenge of the COVID 19 pandemic and that our knowledge of this virus and its effects on the immune system are incomplete including knowledge as to an individual's immunity after COVID‐19 infection. This article is protected by copyright. All rights reserved.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID‐19 and immunosuppressive therapy in dermatology

Schwartz

Pradhan

Murrell

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…We highlight these dermatological drugs and review the adverse effects associated with other drugs being studied. [5][6][7][8]…”

Section: Introduction Imentioning

confidence: 99%

Systemic Medications of Dermatological Importance in COVID-19

Schwartz¹,

Sharma²,

Szepietowski³

et al. 2020

JDD

Self Cite

View full text Add to dashboard Cite

Early December 2019 witnessed an international outbreak of a novel coronavirus (COVID 19) designated severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). Since then, a number of therapeutic molecules have been explored to have potential efficacy against the SARS-Cov-2 per se or its sequelae. There are no Food and Drug Administration specific therapies approved so far; however, numerous drugs based on varying levels of evidence, in vitro studies and compassionate drug trials are being established as therapeutic agents, especially drugs approved for previous emergence of the severe acute respiratory syndrome (SARS-CoV-1) and Middle east respiratory syndrome coronavirus (MERS-Cov). Numerous active clinical trials for COVID-19 with more than 150 drugs and products are under study. Needless to say, many dermatological drugs are being employed to mitigate this pandemic threat. We aim to review drugs with potential against SARS-Cov-2 widely used in dermatology practice. Additionally, rampant and overzealous use of these drugs as well as introduction of new molecules might lead to emergence of adverse effects associated with these agents. Dermatologists must be on lookout for any cutaneous adverse effects of these drugs.

show abstract

“…[1][2][3] The entire world is in the grip of the looming threat of this viral infection. [4][5][6] The World Health Organization (WHO) declared it a health emergency and a pandemic. 7,8 In light of the lack of evidence-based treatments for COVID- 19, repurposing of available medications, including those used by dermatologists, should be considered.…”

Section: Introductionmentioning

confidence: 99%

“…The global public health is currently challenged with the volcanic spread of coronavirus disease (COVID‐19) 1‐3 . The entire world is in the grip of the looming threat of this viral infection 4‐6 . The World Health Organization (WHO) declared it a health emergency and a pandemic 7,8 .…”

Section: Introductionmentioning

confidence: 99%

Utility and risk of dermatologic medications during theCOVID‐19 pandemic

Goldust

Hartmann

Abdelmaksoud

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

In the era of staggering speed in development of the novel coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we have reviewed the dermatologists' tools at hand for their utility (and potential risks) in patients affected by COVID-19. This review aims to shed light on the antiviral and proviral potential of drugs routinely used in dermatology to modulate COVID-19. The literature search included peer-reviewed articles published in the English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) from January 1990 to March 2020 and by reference lists of respective articles. Somewhat to our surprise, we have found that several of our drugs widely used in dermatology have antiviral potential. On the other hand, we also frequently use immunosuppressive drugs in our dermatologic patients that potentially pose them at increased risk for COVID-19.

show abstract

A dermatologist's perspective of the COVID ‐19 outbreak

Cited by 13 publications

References 10 publications

COVID‐19 and immunosuppressive therapy in dermatology

COVID‐19 and immunosuppressive therapy in dermatology

Systemic Medications of Dermatological Importance in COVID-19

Utility and risk of dermatologic medications during theCOVID‐19 pandemic

Contact Info

Product

Resources

About